



# Brief presentation of MLC



## Diagnostics of human health and the environment

# The first flagship product **CGM Fly**

**CGM «Fly»** provides continuous monitoring of blood glucose levels.



Number of countries:    Number of participants:

📍 **173**

👤 **70 000**



**The MLC team is  
an international  
community**

## Management:



**Ivan Saltanov** — Founder, CEO.



**Elena Saltanova** — Co-Founder, CVO.



**Maxim Kolomiets** — Co-Founder, CFO.



**Sergey Melenkov** — Co-Founder, CTO.



**Marina Tmenova** — Co-Founder, Editor-in-Chief.

## Collaboration:



**ARTLEBEDEV**

**Artemy Lebedev Studio** — Industrial design of the CGM device

**FRAXIS**

**FRAXIS** - Development of CGM's electronic components, software



**MegaResearch** — number one marketing agency in Russia


More than 100 people from 15 teams are already engaged in developing the product: IT development and software, electronics and circuitry, design and modeling, research teams from Russia, China, and full-time employees of the laboratory.

# The mission of the MLC project is the CGM Fly product

Making the CGM device available worldwide to diagnose diabetes at early stages, maintain high quality of life for people already diagnosed with the disease, and improve physical performance within the sports sector.

**Our humanitarian mission aims to increase human life expectancy.**

By developing the project, on the one hand, you give everyone in need the opportunity to get this product, on the other hand, you gain financial stability.





## Collaboration with the InnoBioSystems laboratory

# Patents and research

8 patents obtained!




12 more applications are in the works.





# Current stage — 8 of 12



- Expected net funding in installment plans: **\$ 3 million.**
- Distribution: **18% of the company's shares.**
- Main value of the phase: **Bringing the technology to the production phase, certification.**
- Preparing and listing the assets on the exchange.
- Source of funding: **Private small and medium-sized investments attracted worldwide. Receiving payments from sold installment plans.**

# Outlook for the CGM market



The market of continuous glucose monitoring systems has a high growth potential!



MLC commissioned a market research on **CGM** application in the world, as well as an analysis of the prospects and development of the market by **MegaResearch**, a leading marketing agency in Russia.



The potential market volume is **16.7 billion** units. The actual sales volume of **CGM** systems is **0.5%** of the potential one.




Experts forecast an average annual growth in consumption of CGM devices to be **15%**.



By 2045, the market will grow from 98.6 to **2,343.4 million** devices per year (23.8 times), which will be equivalent to the growth from USD **10,953.3 million to USD 233,127.7 million** (21.3 times). At the same time, the supply of devices will amount to **11.5%** of the total number of diabetic patients.

# Transparent legal framework



# Growth prospects for MLC's assets



Total number of shares: **20** billion

Total number of shares for sale: **10** billion

Limited number of investment shares are available for sale.

Seeking to capitalize:

1 MLC investment share = 1 MLC share =  
= **1 dollar**

**Standing with MLC  
for a green future  
and healthy life!**

